Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Earnings Call Insights: Exagen Inc. (XGN) Q2 2025

MANAGEMENT VIEW

* John Aballi, CEO, stated that "Q2 revenue came in at $17.2 million, representing 14% year-over-year growth and the highest quarterly revenue in company history." He highlighted substantial AVISE CTD test volume growth, noting it was "the best quarterly volume since we made our strategic adjustments in the summer of 2023." The CEO emphasized that this growth was driven organically by the existing commercial team and clinical recognition of Exagen's differentiated science. He also pointed to a "per territory revenue" of just over $430,000 for the quarter, marking over 50% growth since his tenure began.
* Aballi discussed recent progress, including the successful launch of new T cell and RA biomarkers, stating, "The addition of novel T cell and RA markers has been a meaningful catalyst in our commercial conversations." He described multiple clinical anecdotes illustrating the impact of AVISE’s new markers on diagnosis and patient outcomes, supporting the platform's growing adoption.
* Two significant leadership additions were announced: "We welcome Dr. Michael Mahler, as our new Chief Scientific Officer... and Chas McKhann to our Board of Directors." Mahler’s expertise in biomarker development is expected to support upcoming launches.
* The CEO reported R&D pipeline progress, including advancements in lupus nephritis markers, additional validation cohorts for blood-based kidney damage biomarkers, and the plan to submit anti-PAD4 biomarkers for regulatory review in August, aiming for a commercial launch heading into 2026.
* Jeffrey G. Black, CFO, stated, "We delivered $17.2 million in the second quarter, a 14% increase over 2024 and this growth came from an increase in volume, which was up 14% sequentially from the first quarter and 7% from the second quarter of 2024 as well as continued ASP expansion." Black highlighted that gross margin improved to just over 60% and operating expenses were $13 million, including one-time items and ongoing R&D investments. He confirmed, "Our net loss for the second quarter was $4.4 million compared to $3 million in the same period last year." Black noted a strong balance sheet with "over $40 million in combined cash and accounts receivable at June 30 and up to an additional $50 million in available future credit capacity."

OUTLOOK

* The company reaffirmed its guidance, with Black stating, "we're providing full year revenue guidance of between $65 million and $70 million and at the high end of that range, we'd expect to hit positive adjusted EBITDA in the fourth quarter and on a sustainable basis throughout 2026."
* The CEO stated, "the expected impact of our sales expansion likely won't be felt until at least Q4, further accelerating our trajectory." Both management and the board expressed confidence in continued gross margin and ASP improvements, along with sustainable volume growth.

FINANCIAL RESULTS

* Exagen reported Q2 revenue of $17.2 million, a 14% year-over-year increase. AVISE CTD average selling price (ASP) for the trailing 12 months rose to $428, up $27 from the prior year, driven by new biomarkers. Gross margin was just over 60%, up from about 59% in the first quarter. Operating expenses reached $13 million, reflecting investments in R&D and commercial expansion. Net loss stood at $4.4 million for the quarter. Operating cash burn was just under $3 million for Q2, with $30 million in cash, cash equivalents, and restricted cash at quarter end.

Q&A

* William Ruby, TD Cowen: Questioned sustainability of volume growth and contributions of new markers. Aballi responded that growth is "attributed to the strong team that we've established" and the new markers "absolutely proven to be a valuable contribution... gives our team something new to talk to clinicians about plus the value proposition that we've conveyed is panning out in first-hand examples." He affirmed, "We think this is very sustainable. We have a large market, and we're around just under 10% penetrated."
* Ruby inquired about ASP progress towards a $90 increase. Aballi explained, "I am very bullish on our ability to continue to drive this number higher over time... we did make some adjustments to a few accrual rates, which brought them closer to what we're seeing from a cash collection standpoint real time... we do still feel very bullish with the $90, potentially even higher than that is absolutely where we should sit."
* Kyle Mikson, Canaccord: Asked about volume seasonality and pipeline launches. Aballi described Q2 as "a fantastic quarter" and expected sales expansion to offset traditional seasonality in the back half. On new tests, Aballi said, "We plan to launch two additional markers... anti-PAD antibodies... should actually be a tailwind to ASP."
* Mikson probed on biopharma pipeline. Aballi noted "a concerted effort with a dedicated team" and expects biopharma revenue to "be a contributing factor in the back half."
* Margarate Elizabeth Boeye, William Blair: Asked about territory expansion and ASP levers. Aballi stated, "we started the quarter right around 40 territories... got to 42... we have a line of sight to 2 more additions here, call it, Q3, early Q4." On ASP: "Our blended ASP now here at the end of Q2 is $428. So we have some meaningful opportunity... for continued improvement there."
* Ross Everett Osborn, Cantor Fitzgerald: Asked about market access initiatives. Aballi detailed ongoing digital campaigns, KOL partnerships, and the importance of field-based reps to drive adoption.

SENTIMENT ANALYSIS

* Analysts focused on sustainability of volume growth, ASP expansion, and the impact of new product launches, reflecting a neutral to slightly positive tone with repeated congratulations and requests for clarification rather than skepticism.
* Management maintained a confident and optimistic tone throughout, emphasizing operational discipline, sustainable growth, and strategic flexibility. Aballi used phrases such as "I am very bullish" and "we think this is very sustainable," while Black stated, "We delivered another record revenue quarter."
* Compared to the previous quarter, the tone from both analysts and management remained confident, with continued emphasis on execution and growth, but with additional focus on the impact of the expanding product pipeline and territory growth.

QUARTER-OVER-QUARTER COMPARISON

* Guidance for 2025 revenue ($65 million–$70 million) is consistent with the previous quarter, but now explicitly tied to achieving positive adjusted EBITDA in Q4 and sustainable profitability in 2026.
* Strategic focus has shifted further toward scaling commercial and scientific teams, with new leadership hires and board additions highlighted as key drivers.
* Analysts’ questions continued to focus on volume growth and ASP, but there was increased interest in the timeline and impact of new biomarker launches and the company’s expanding field presence.
* Key financial metrics showed improvement: record revenue, higher ASP, and gross margin expansion. Management tone remains confident, echoing the previous quarter, but with more emphasis on operational leverage and R&D pipeline progress.

RISKS AND CONCERNS

* Management cited the potential for traditional seasonality to impact volume in the second half but pointed to sales force expansion as a mitigating factor.
* Adjustments to accrual rates on new biomarkers were made to align with cash collections, which may impact short-term ASP realization but are described as prudent risk management.
* Analysts raised concerns about ASP trajectory, sustainable volume growth, and the timing of new product launches, with management reiterating confidence in their strategy and financial flexibility.

FINAL TAKEAWAY

Exagen Inc. management underscored a record-setting quarter driven by organic test volume growth, increased ASP, and ongoing innovation in autoimmune diagnostics. With a reinforced leadership team, focused commercial expansion, and a robust R&D pipeline, the company reiterated its full-year revenue guidance of $65 million–$70 million and a clear expectation to achieve positive adjusted EBITDA in the fourth quarter. Management expressed strong confidence in the sustainability of recent growth, continued margin expansion, and the long-term value creation for patients, clinicians, and shareholders.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/xgn/earnings/transcripts]

MORE ON EXAGEN

* Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4805713-exagen-inc-xgn-q2-2025-earnings-call-transcript]
* Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4781930-exagen-inc-xgn-q1-2025-earnings-call-transcript]
* Exagen GAAP EPS of -$0.21 misses by $0.06, revenue of $17.2M beats by $0.89M [https://seekingalpha.com/news/4473251-exagen-gaap-eps-of-0_21-misses-by-0_06-revenue-of-17_2m-beats-by-0_89m]
* Exagen prices public offering of common stock [https://seekingalpha.com/news/4444520-exagen-prices-public-offering-of-common-stock]
* Seeking Alpha’s Quant Rating on Exagen [https://seekingalpha.com/symbol/XGN/ratings/quant-ratings]